103 related articles for article (PubMed ID: 19274615)
1. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
[TBL] [Abstract][Full Text] [Related]
2. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Press RD; Willis SG; Laudadio J; Mauro MJ; Deininger MW
Blood; 2009 Sep; 114(13):2598-605. PubMed ID: 19625707
[TBL] [Abstract][Full Text] [Related]
3. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
Jabbour EJ; Cortes JE; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):515-29. PubMed ID: 23890944
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
Hughes TP; Saglio G; Quintás-Cardama A; Mauro MJ; Kim DW; Lipton JH; Bradley-Garelik MB; Ukropec J; Hochhaus A
Leukemia; 2015 Sep; 29(9):1832-8. PubMed ID: 26118315
[TBL] [Abstract][Full Text] [Related]
5. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).
Berman E; Jhanwar S; Hedvat C; Arcila ME; Wahab OA; Levine R; Maloy M; Ma W; Albitar M
Leuk Res; 2016 Oct; 49():108-12. PubMed ID: 27658269
[TBL] [Abstract][Full Text] [Related]
6. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
[TBL] [Abstract][Full Text] [Related]
7. Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report.
Li X; Cai S; Zhong Z; Wang H; Wang L; You Y; Zhang M
Medicine (Baltimore); 2020 Feb; 99(9):e19256. PubMed ID: 32118733
[TBL] [Abstract][Full Text] [Related]
8.
Azevedo AP; Reichert A; Afonso C; Alberca MD; Tavares P; Lima F
Clin Med Insights Oncol; 2017; 11():1179554917702870. PubMed ID: 28469513
[TBL] [Abstract][Full Text] [Related]
9. Structural mechanism of a drug-binding process involving a large conformational change of the protein target.
Ayaz P; Lyczek A; Paung Y; Mingione VR; Iacob RE; de Waal PW; Engen JR; Seeliger MA; Shan Y; Shaw DE
Nat Commun; 2023 Apr; 14(1):1885. PubMed ID: 37019905
[TBL] [Abstract][Full Text] [Related]
10. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.
Perusini MA; Žáčková D; Kim T; Pagnano K; Pavlovsky C; Ježíšková I; Kvetková A; Jurček T; Kim J; Yoo Y; Yi S; Lee H; Kim KH; Chang M; Capo-Chichi JM; Medeiros JJF; Arruda A; Minden M; Zhang Z; Abelson S; Mayer J; Hwan Kim DD
Blood Adv; 2024 May; 8(10):2361-2372. PubMed ID: 38447114
[TBL] [Abstract][Full Text] [Related]
11. The Mozart effect in chronic myeloid leukaemia.
Stentoft J
Br J Haematol; 2024 Apr; 204(4):1139-1140. PubMed ID: 38375783
[TBL] [Abstract][Full Text] [Related]
12. Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism.
Wilson C; Agafonov RV; Hoemberger M; Kutter S; Zorba A; Halpin J; Buosi V; Otten R; Waterman D; Theobald DL; Kern D
Science; 2015 Feb; 347(6224):882-6. PubMed ID: 25700521
[TBL] [Abstract][Full Text] [Related]
13. CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML.
Absar M; Alanazi N; Siyal A; Shammas M; Mahmood A; Basit S; AlMukhaylid S; Iqbal Z
J Popul Ther Clin Pharmacol; 2022 Jun; 29(2):311-320. PubMed ID: 38465242
[TBL] [Abstract][Full Text] [Related]
14. Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Carella AM; Garuti A; Cirmena G; Catania G; Rocco I; Palermo C; Pica G; Pierri I; Miglino M; Ballestrero A; Gobbi M; Patrone F
Leuk Lymphoma; 2010 Feb; 51(2):275-8. PubMed ID: 20038234
[TBL] [Abstract][Full Text] [Related]
15. A customized mass array panel for
Limsuwanachot N; Rerkamnuaychoke B; Niparuck P; Singdong R; Kongruang A; Hirunpatrawong P; Siriyakorn T; Yenchitsomanus PT; Siriboonpiputtana T
J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():122-132. PubMed ID: 37128502
[TBL] [Abstract][Full Text] [Related]
16. Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation.
Uhm J
Blood Res; 2023 Apr; 58(S1):109-113. PubMed ID: 37105565
[TBL] [Abstract][Full Text] [Related]
17. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era.
Shi T; Xie M; Chen L; Yuan W; Wang Y; Huang X; Xie W; Meng H; Lou Y; Yu W; Tong H; Ye X; Huang J; Jin J; Zhu H
Exp Hematol Oncol; 2022 Mar; 11(1):13. PubMed ID: 35277197
[TBL] [Abstract][Full Text] [Related]
18. Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature.
Amouei A; Daeian N; Khezrnia SS; Mansouri A; Hadjibabaie M
Int J Hematol Oncol Stem Cell Res; 2021 Apr; 15(2):114-131. PubMed ID: 34466210
[No Abstract] [Full Text] [Related]
19. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
20. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
